ATE286743T1 - Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten - Google Patents

Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten

Info

Publication number
ATE286743T1
ATE286743T1 AT98956455T AT98956455T ATE286743T1 AT E286743 T1 ATE286743 T1 AT E286743T1 AT 98956455 T AT98956455 T AT 98956455T AT 98956455 T AT98956455 T AT 98956455T AT E286743 T1 ATE286743 T1 AT E286743T1
Authority
AT
Austria
Prior art keywords
carriers
pharmaceutical compositions
containing amphiphilic
medication
compositions containing
Prior art date
Application number
AT98956455T
Other languages
English (en)
Inventor
Janos Szebeni
Carl R Alving
Original Assignee
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army filed Critical Us Army
Application granted granted Critical
Publication of ATE286743T1 publication Critical patent/ATE286743T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT98956455T 1997-10-31 1998-10-30 Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten ATE286743T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6387697P 1997-10-31 1997-10-31
PCT/US1998/023280 WO1999022759A1 (en) 1997-10-31 1998-10-30 Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules

Publications (1)

Publication Number Publication Date
ATE286743T1 true ATE286743T1 (de) 2005-01-15

Family

ID=22052087

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98956455T ATE286743T1 (de) 1997-10-31 1998-10-30 Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten

Country Status (7)

Country Link
US (2) US7419683B2 (de)
EP (1) EP0996461B1 (de)
AT (1) ATE286743T1 (de)
AU (1) AU1297899A (de)
CA (1) CA2298475A1 (de)
DE (1) DE69828615T2 (de)
WO (1) WO1999022759A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
JP2000016948A (ja) 1998-04-30 2000-01-18 Noda Inst For Scient Res コンプレスタチンまたはその誘導体を有効成分とするｆｇｆ阻害剤、血管新生阻害剤および抗腫瘍剤
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
EP2231190B1 (de) 2007-12-06 2012-09-26 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Partikelwirkstoffträger als desensibilisierungswirkstoffe
EP2204167A1 (de) 2009-01-05 2010-07-07 Azad Pharma AG Pharmazeutische Mikroemulsion zur Prävention von supramolekularer Aggregation von ampiphilen Molekülen
CN104203251B (zh) * 2012-03-22 2017-05-31 盐水港精糖株式会社 内包紫杉醇单糖苷和/或紫杉萜单糖苷的脂质体的制造方法
CA2871821C (en) 2012-05-10 2021-01-12 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
EP3291797B1 (de) * 2015-05-04 2020-09-02 Versantis AG Verfahren zur herstellung von transmembranen ph-gradienten-vesikeln
CN108495619A (zh) * 2015-11-10 2018-09-04 儿研所儿童医学中心 棘霉素制剂及其制备方法和使用方法
CA3047326A1 (en) * 2016-12-21 2018-06-28 Arbutus Biopharma Corporation Methods for ameliorating infusion reactions
US20220356234A1 (en) * 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO109863B1 (ro) * 1989-10-12 1995-06-30 Imutran Ltd Gena care codifica cel putin un factor de restrictie complementar, animal transgenic si metode de transplantare a tesuturilor sau organelor animale
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
ES2208884T3 (es) * 1996-01-25 2004-06-16 Schering Aktiengesellschaft Soluciones mejoradas de agentes de contraste para la administracion intravasal.

Also Published As

Publication number Publication date
EP0996461A1 (de) 2000-05-03
WO1999022759A1 (en) 1999-05-14
CA2298475A1 (en) 1999-05-14
US20020136759A1 (en) 2002-09-26
US7419683B2 (en) 2008-09-02
EP0996461B1 (de) 2005-01-12
AU1297899A (en) 1999-05-24
DE69828615T2 (de) 2005-12-01
US20080107724A1 (en) 2008-05-08
WO1999022759A9 (en) 1999-08-12
DE69828615D1 (de) 2005-02-17

Similar Documents

Publication Publication Date Title
ATE286743T1 (de) Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
KR920004395A (ko) 수소화된 라파마이신 유도체
AR003415A1 (es) Compuestos analogos de lactacistina, metodo para inhibir la proteolisis dependiente de proteasoma, metodo para identificar un proceso biologico mediado por proteolisis dependiente de proteasoma, uso de dichos compuestos para preparar un medicamento para tratar una condicion mediada por proteolisis dependiente de proteasoma.
ATE73657T1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
HUP9802857A2 (hu) Farnezil-transzferáz gátló hatású 4-merkapto-pirrolidin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
DE3687501D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
KR960703585A (ko) 재발협착증의 억제 방법(Method to inhibit restenosis)
ATE152910T1 (de) Verwendung von taxol zur herstellung eines arzneimittels zur behandlung von krebs
ATE210441T1 (de) Arzneizusammensetzungen enthaltnd hiv - proteaseinhibitoren
MD1507G2 (ro) Inhibitori, compoziţie farmaceutică pe baza lor şi procedeu de inhibare a HIV proteazei
ID21696A (id) Turunan asam antranilat sebagai modulator resistensi multi obat
RU95110938A (ru) Производные 1-(2-оксоацетил)пиперидин-2-карбоновых кислот, фармацевтическая композиция, способ лечения, способ получения
KR950007859A (ko) 경구 투여용 라파마이신 제형
AR002751A1 (es) Antifungicos de tetrahidrofurano, composiciones farmaceuticas que los contienen y el uso de los compuestos para preparar composiciones farmaceuticas utiles para el tratamiento de infecciones fungicas
FR2718963B1 (fr) Nouvelle composition pharmaceutique à base de taxoïdes.
ES2113664T3 (es) Derivados de aminoacidos como inhibidores de la no sintasa.
DE60004630D1 (de) Arzneimittel und verfahren zur verabreichung von wasserunlöslichen paclitaxelderivaten
DE69632193D1 (de) Cyclooxygenaseinhibitor und salze von amidinderivaten, verfahren zu deren herstellung, deren verwendung als arzneiwirkstoffe sowie diese salze enthaltende arzneimittel
KR890014494A (ko) 치환된 7-하이드록시-2,3,4,5-테트라하이드로-1h-3-벤즈아제핀의 카밤산 에스테르
PT1057826E (pt) Derivados carboxamidicos dimericos substituidos processo para a sua preparacao e as composicoes farmaceuticas que os contem
KR900017586A (ko) 케탄세린(ketanserin) 유도체
ATE329592T1 (de) Pharmazeutische produkte zur heilung und vorbeugung von krankheiten, die aus der beschädigung der vaskulären endothelzellen hervorgehen
KR910000607A (ko) 새로운 에스테르
ATE353321T1 (de) Dreiringige verbindungen, verfahren zu ihrer herstellung und zwischenprodukte dieses verfahren,ihre anwendung als arzneimittel und sie enthaltende pharmazeutische zusammensetzungen
KR970701044A (ko) 콜린에스테라제 활성제

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties